RNLX: Renalytix PLC Company Short-Term Debt

Renalytix Plc (RNLX) automates renal risk assessment via the KidneyIntelX AI system, minimizing physician errors. This price chart illustrates debt dynamics, which currently stands at 0.00. The business relies on the early detection of pathologies through blood analysis, ensuring demand from clinics. However, a slow adoption rate of the tests limits revenue, preventing the company from covering laboratory fixed costs and reducing the cost of goods sold.

Renalytix Plc (RNLX) innovative diagnostic systems require high liquidity to mitigate risks of global supply chain disruptions and market losses resulting from geopolitical sanctions. By analyzing the company's short-term liability structure, an investor assesses the total amount of loans maturing within one year, where rising levels signal a working capital deficit and a decline in the asset's investment attractiveness.